Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea

The course of sickle cell disease (SCD) is modified by polymorphisms boosting fetal hemoglobin (HbF) synthesis. However, it has remained an open question how these polymorphisms affect patients who are treated with the HbF-inducing drug hydroxyurea/ hydroxycarbamide. The German SCD registry offers t...

Descripción completa

Detalles Bibliográficos
Autores principales: Allard, Pierre, Alhaj, Nareen, Lobitz, Stephan, Cario, Holger, Jarisch, Andreas, Grosse, Regine, Oevermann, Lena, Hakimeh, Dani, Tagliaferri, Laura, Kohne, Elisabeth, Kopp-Schneider, Annette, Kulozik, Andreas E., Kunz, Joachim B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Hemoglobinopathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244815/
https://www.ncbi.nlm.nih.gov/pubmed/34706496
http://dx.doi.org/10.3324/haematol.2021.278952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244815/
https://www.ncbi.nlm.nih.gov/pubmed/34706496
http://dx.doi.org/10.3324/haematol.2021.278952

Ejemplares similares